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Emerging evidence showed that long non-coding RNAs (lncRNAs) play important roles in a wide range of
biological processes and dysregulated lncRNAs are involved in many complex human diseases, including cancer.
Although a few lncRNAs’ functions in cancer have been characterized, the detailed regulatory mechanisms of
majority of lncRNAs in cancer initiation and progression remain largely unknown. In this review, we summarized
recent progress on the mechanisms and functions of lncRNAs in cancer, especially focusing on the oncogenic and
tumor suppressive roles of the newly identified lncRNAs, and the pathways these novel molecules might be
involved in. Their potentials as biomarkers for diagnosis and prognosis in cancer are also discussed in this paper.Introduction
Genome-wide transcriptome studies have revealed that
there exist a large number of non-coding RNAs
(ncRNAs), including short and long non-coding RNAs
[1,2]. Short ncRNAs have a length of under 200 nucleo-
tides (nt) and include small interfering RNAs (siRNAs,
21-25 nt), piwi-associated RNAs (piRNAs, 24-33 nt) and
well-documented microRNAs (miRNAs, 21-25 nt), while
long ncRNAs (lncRNAs) are greater than 200 nt in length,
frequently ranging up to 100 kb [3]. It has been known
that lncRNAs, mRNA-like transcripts, are mainly tran-
scribed by RNA polymerase II (RNA PII) and are
polyadenylated, spliced, and mostly localized in the nu-
cleus [3-5].
Recent studies estimated that the number of lncRNAs
in humans is approximately 15,000 and found that most
lncRNAs displayed tissue-specific expression patterns [6].
Based on their locations and characteristics, lncRNAs can
be categorized into five subgroups: (1) sense, (2) antisense,
(3) bidirectional, (4) intronic, and (5) intergenic [5]. In-
creasing studies have indicated that lncRNAs play import-
ant roles in a wide range of biological processes including
stress response [7], development [8], embryonic stem cell
pluripotency [9], localization [10], alternative splicing [11],
chromatin remodeling [12] and mRNA decay [13].* Correspondence: zhiweihe688@yahoo.com; lsscyq@mail.sysu.edu.cn
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reproduction in any medium, provided the orFurthermore, lncRNAs can affect many cellular processes,
such as cell cycle [14], survival [15], migration [16] and
metabolism [17].
Because lncRNAs, like miRNAs, function as key regula-
tors in gene regulation, it is not surprising that
dysregulated lncRNAs are involved in many complicated
human diseases including cancer. Mounting evidence
showed that many lncRNAs, similar to miRNAs, have al-
tered expression in various types of human cancer and
dysregulated lncRNAs function as tumor suppressors or
oncogenes [18,19]. Undoubtedly, lncRNAs have become
new players in cancer after miRNAs although the detailed
mechanisms of most lncRNAs remain largely unknown.
In this review, we overviewed the roles of lncRNAs in
tumorigenesis, focusing on the currently known mecha-
nisms and functions of lncRNAs, and their potentials as
biomarkers and targets for novel therapeutic approaches
in the future.
Regulatory mechanisms of lncRNAs
It has been known that ncRNAs function as a new class of
regulators involved in a complicated molecular network,
controlling gene expression and cellular activity. Among
them, well-documented miRNAs were known to regulate
gene expression at either the transcriptional or the post-
transcriptional level usually by base-pairing to the 3′-un-
translated region (3′ UTR) of target mRNAs with the
miRNA 5′-proximal “seed” region (positions 2-8) in ani-
mals [20]. However, compared with miRNA, the regula-
tory mechanisms of lncRNA are more challenging to
characterize, since these molecules are neither as con-
served nor as abundantly expressed as miRNAs [21].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression by diverse mechanisms.
Guiding role of lncRNAs in cis and in trans
Evidence showed that lncRNAs can bind and ‘guide’ chro-
matin modifying complexes to specific genomic sites to
induce epigenetic changes and regulate gene expression in
cis (on neighboring genes of the same chromosome) or in
trans (on distantly located genes of the same or different
chromosome) [22]. Several early discovered cis-regulatory
lncRNAs were well-studied. For example, XIST repres-
ses genes on X chromosome by the recruitment of
PRC2 (polycomb repressive complex 2) [23]; AIR and
KCNQ1OT1 silence transcription of their target genes by
recruiting G9a [24,25]; HOTTIP recruits the MLL histone
H3 lysine 4 (H3K4) methyltransferase complex to main-
tain active chromatin [26]. LncRNAs can also regulate
gene expression by guiding site-specific recruitment of
chromatin modifying complexes in trans. It has been
shown the lncRNA HOTAIR mediates the epigenetic
repression by increasing PRC2 and LSD1 recruitment to
the genomic positions of target genes [16]. In addition,
PCAT-1, JPX and lincRNA-p21 function by trans-reg-
ulation of genes [27-29]. Interestingly, the lncRNA
asOct4-ps5, an antisense to a pseudogene of Oct4, could
regulate Oct4 by guiding the histone methyltransferase
Ezh2 to the Oct4 promoter in trans [30].
Serving as scaffolds
Another regulation mechanism of lncRNAs is to serve as
scaffolds. Studies demonstrated that lncRNA KCNQ1OT1
could bind both G9a and PRC2, and lncRNA HOTAIR
could interact with PRC2 and LSD1, revealing these
lncRNAs can serve as scaffolds for chromatin-modifying
complexes besides their guide role [25,26]. Similarly,
lncRNA ANRIL and NEAT1 were also found acting as
scaffolds [31-33]. In addition, it was found that appro-
ximately 38% of large intergenic non-coding RNAs
(lncRNAs) expressed in the cell types studied are reprodu-
cibly associated with chromatin-modifying complexes
(PRC2, CoREST and SMCX) by RNA coimmunopre-
cipitation (RIP) with antibodies directed against several
proteins involved in these complexes [34]. Thus, these
studies implied that lincRNAs bind to chromatin modify-
ing complexes first to serve as scaffolds, and then guide
the complexes to specific genomic regions.
Transcriptional regulation
LncRNAs regulate gene expression at transcriptional level
via multiple mechanisms. It was reported that by compet-
ing for binding sites, the lncRNA GAS5 (growth arrest
specific 5) interacts directly with the DNA binding do-
main of glucocorticoid receptors (GR), preventing them
from binding to their DNA response elements, thusfunctions in transcription inhibition as a molecular decoy
[17]. In addition, recent studies revealed that novel classes
of promoter-associated lncRNAs, the promoter upstream
transcripts (PROMPTs) and enhancer-associated lncRNAs
(eRNAs), are positively correlated with the level of mes-
senger RNA synthesis and regulate the transcription activ-
ity of host protein-coding genes (PCGs) [35,36].
Alternative splicing and translational regulation
The well-known example of mRNA splicing mediated by
lncRNAs is that lncRNA MALAT1 interacts with the
serine/arginine-rich splicing regulatory (SR) proteins in-
volved in alternative splicing, suggesting that the lncRNA
MALAT1 may serve a function in the regulation of alter-
nate splicing [11]. Another example of translational regu-
lation for lncRNAs is that lncRNA BACE1-AS can
interact with the β-site APP (amyloid precursor protein)
cleaving enzyme 1 (BACE1) transcript and increase
BACE1 mRNA stability, thus generate more gene product
[37]. Notably, some pseudogenes have been found to regu-
late translation. For example, lncRNA pseudo-NOS, a
pseudogene of nitric oxide synthase (NOS), can bind and
repress translation of nNOS (neuronal nitric oxide syn-
thase) gene through influencing the association of the
ribosome with the nNOS–pseudo-NOS duplex [38].
Another representative mechanism is that some lncRNAs
including pseudogenes, such as lncRNA PTENP1, a
pseudogene of PTEN, serve as ‘sponges’ to prevent spe-
cific miRNAs from binding to their target mRNAs by
competitively binding to miRNAs [39,40].
Dysregulated lncRNAs in cancer
Transcriptional profiling has revealed highly aberrant
lncRNA expression in human cancers [41]. Though the
function of most lncRNAs remains unknown, accumulat-
ing evidence showed that differentially expressed lncRNAs
are associated with cancer pathogenesis and function as
new regulators in cancer development. These dysregulated
lncRNAs in cancer are listed in Table 1. In this section, we
mainly discussed their potentials as biomarkers, and their
functions as oncogenes and tumor suppressors, as well as
the molecular pathways they might be involved in.
Serving as biomarkers for diagnosis and prognosis
Seeking novel molecular biomarkers of malignancy is
always important and helpful for clinical diagnosis
and management. Like proteins, mRNAs and miRNAs,
lncRNAs show their potentials as novel independent
biomarkers for early diagnosis and prognosis prediction in
cancer.
It has been found that lncRNA HOTAIR is highly
upregulated in breast cancer, hepatocellular carcinoma
(HCC), colorectal cancer and gastrointestinal stromal tu-
mors (GIST). Furthermore high HOTAIR gene expression
Table 1 Examples of dysregulated lncRNAs in cancer
lncRNA Cancer type Expression Function Reference
MVIH Hepatocellular Upregulated Biomarker [42]
DD3
(PCA3)
Prostate Upregulated Biomarker [43]
HOTAIR Breast, hepatocellular, colorectal, gastrointestinal stromal Upregulated Biomarker [16,44-47]
Oncogenic [16,48]
MALAT1 Lung, hepatocellular Upregulated Biomarker [49-51]
Lung, liver, renal cell, breast, cervical, uterine endometrial stromal, colorectal, bladder,
osteosarcoma
Oncogenic [52]
H19 Hepatocellular Downregulated Biomarker [53]
Hepatocellular, bladder Upregulated Oncogenic [54]
PCAT-1 Prostate Upregulated Oncogenic [27]
PCGEM1 Prostate Upregulated Oncogenic [55]
TUC338 Hepatocellular Upregulated Oncogenic [56]
BANCR Melanoma Upregulated Oncogenic [57]
YIYA Hepatocellular, ovary, breast, esophageal Upregulated Oncogenic [58]
CRNDE Colorectal, hepatocellular, pancreatic, prostate, ovarian, leukemia, gliomas Upregulated Oncogenic [59]
CCAT1 Gastric Upregulated Oncogenic [60]
HULC Hepatocellular Upregulated Oncogenic [61]
CUDR Bladder Upregulated Oncogenic [62]
GAS5 Breast Downregulated Tumor
suppressive
[63]
linc-p21 Mouse models of lung, sarcoma, lymphoma Downregulated Tumor
suppressive
[29]
MEG3 Meningioma, glioma, hepatocellular, leukemia Downregulated Tumor
suppressive
[64-67]
PTENP1 Prostate, colon Downregulated Tumor
suppressive
[40]
PTCSC3 Papillary thyroid Downregulated Tumor
suppressive
[68]
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poor survival rate in breast cancer, increasing risk of re-
currence after hepatectomy in HCC and high-risk grade
in GIST, indicating HOTAIR may be a useful biomarker
of poor prognosis and tumor metastasis in these cancers
[16,44-47]. In HCC, another lncRNA MVIH was found
overexpressed and significantly associated with frequent
microvascular invasion, higher tumor node metastasis
stage, decreased recurrence-free survival (RFS) and overall
survival, revealing that the upregulation of MVIH can
serve as an independent risk factor to predict poor RFS
[42]. More recently, it was reported that lncRNA H19 is
underexpressed in intratumoral HCC tissues (T), as com-
pared with peritumoral tissues (L), and low T/L ratio of
H19 is associated with shorter disease-free survival and
can be used to predict poor prognosis [53]. Studies also
showed that lncRNA MALAT1 is upregulated and serves
as an independent prognostic parameter for patient sur-
vival in early stage non-small-cell lung cancer [49,50].
LncRNA MALAT1 can also be used for predicting HCCrecurrence after liver transplantation in HCC [51]. In
prostate cancer, highly expressed lncRNA DD3 (PCA3)
demonstrated better diagnostic efficiency than another
promising biomarker telomerase reverse transcriptase
(hTERT gene) for prostate cancer, and could be easily
detected in prostate needle biopsies or bodily fluids such
as blood, ejaculate, urine, or prostate massage fluid, thus
lncRNA DD3 is a very sensitive and specific biomarker for
the detection of prostate tumor cell [43].
Genome-wide association studies (GWAS) have re-
vealed a large number of genetic variants related to dis-
eases, including cancer. Recently, genetic variations in
lncRNAs and their associations with cancer susceptibility
have been reported, suggesting single nucleotide polymor-
phisms (SNPs) may also serve as biomarkers for diagnosis
and prognosis. Studies showed that SNP rs2151280 in
lncRNA ANRIL was significantly associated with higher
number of plexiform neurofibromas (PNFs) in neuro-
fibromatosis type 1 (NF1) patients, which suggests SNP
rs2151280 in lncRNA ANRIL is a potential biomarker for
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variant genotype of rs7763881 in lncRNA HULC is signi-
ficantly associated with decreased risk to HCC in hepa-
titis B virus (HBV) persistent carriers, while variant
rs10680577 within lncRNA RERT is a promising bio-
marker for early diagnosis of HCC [70,71]. Another recent
study found that two genetic variations (rs6434568 and
rs16834898) in lncRNA PCGEM1 might increase prostate
cancer (PCa) risk [72].
Oncogenic and tumor suppressive lncRNAs
Like protein-coding genes and miRNAs, lncRNAs can
function as oncogenes or tumor suppressors during can-
cer progression. A further investigation of the roles and
mechanisms of lncRNAs in cancer will provide novel
lncRNA-based strategies for the treatment of human can-
cers. Some well-studied lncRNAs, such as HOTAIR
[16,48], MALAT1 [52], PCAT-1 [27], PCGEM1 [55],
TUC338 [56], were reported as oncogenes, while GAS5
[63], linc-p21 [29], MEG3 [64] and PTENP1 [40] were
reported as tumor suppressors. Here, we mainly focus on
recently studied lncRNAs.
The newly identified lncRNA BANCR was found
overexpressed in melanoma and required for full migra-
tory capacity of melanoma cells by upregulating CXCL11,
an important gene involved in cell migration, revealing
the potential functional role of lncRNA BANCR [57]. An-
other novel lncRNA YIYA is upregulated in different can-
cers and promotes cell cycle progression at the G1/S
transition, demonstrating it is a carcinogenesis-associated
lncRNA [58]. A recent study found that lncRNA CRNDE
is highly elevated in many solid tumors and in acute mye-
loid leukemias (AML), especially in M2 AML and M3
AML, and lncRNA CRNDE can promote cell growth and
suppress apoptosis, which supports a role for CRNDE as a
mediator of oncogenesis [59]. More recently, it was
reported that lncRNA CCAT1, activated by c-Myc, is
markedly increased in gastric carcinoma and promote cell
proliferation and migration, implicating CCAT1 as a po-
tential therapeutic target [60]. Studies also showed that in-
duction of lncRNA HULC by Hepatitis B virus X protein
(HBx) promotes proliferation of hepatoma cells through
downregulating tumor suppressor gene p18 in vitro and
in vivo [61]. In addition, it was found that lncRNA CUDR,
a variant transcript of lncRNA UCA1, is upregulated in
various human tumors and can significantly enhance pro-
liferation, migration and invasion of the bladder cancer
cell in vitro and in vivo, indicating lncRNA CUDR func-
tions as an oncogene and may serve as a novel therapeutic
target for bladder cancer [62]. Compared with these onco-
genic lncRNAs, some lncRNAs showed a tumor suppres-
sive role. The lncRNA MEG3 (maternally expressed gene
3), which is associated with meningioma pathogenesis and
progression [64], was recently found markedly decreasedin glioma tissues and ectopic expression of lncRNA
MEG3 inhibited cell proliferation and promoted cell apop-
tosis via p53 activation in human glioma [65]. Very inter-
estingly, a study reported that lncRNA PTCSC3 (Papillary
Thyroid Carcinoma Susceptibility Candidate 3), located
3.2 kb downstream of SNP rs944289 at 14q.13.3, is
strongly downregulated in papillary thyroid carcinoma
(PTC). The overexpression of lncRNA PTCSC3 could in-
hibit PTC cell growth and affected the expression of genes
involved in DNA replication, recombination and repair,
cellular movement, tumor morphology, and cell death, im-
plying that lncRNA PTCSC3 has the characteristics of a
tumor suppressor [68]. Further study revealed that SNP
rs944289 abolishes the binding site of both C/EBPα and
C/EBPβ, which bind and activate the PTCSC3 promoter,
thus, SNP rs944289 predisposes to PTC through down-
regulating tumor suppressive lncRNA PTCSC3 [68].
Pathways involving lncRNAs in cancer
Differentially expressed lncRNAs between cancer and nor-
mal tissues indicate these lncRNAs may exert a key role in
cancer development. Understanding the pathways lncRNAs
involved in helps to provide further insights into the patho-
genesis of cancer. In HCC, PKA-mediated phosphorylation
of CREB leads to formation of the CREB-p300-Brg I com-
plex, loading of the CREB-p300-Brg I complex onto the
lncRNA HULC promoter, and consequent activation of
HULC expression [73]. In addition, lncRNA HULC can
be activated by HBx via CREB protein and promotes prolif-
eration of hepatoma cells through suppressing p18, an
activator of p53 through its interaction with ataxia
telangiectasia-mutated (ATM) in response to DNA damage
[61,74]. These results suggest that lncRNA HULC also is
involved in the ATM/P53 pathway in HCC. In bladder
cancer, lncRNA UCA1 upregulates CREB activity through
enhancing AKT activity, while blocking PI3-K pathway by
PI3 Kinase inhibitor can downregulate lncRNA UCA1 ex-
pression and reduce cell cycle progression. These findings
indicate lncRNA UCA1 promotes cell proliferation and reg-
ulates cell cycle progression through CREB via PI3-K/AKT
dependent signaling pathway [75]. Another lncRNA CUDR
may promote tumorigenesis through upregulating PDGFB
in tumorigenesis pathway and downregulating FAS and
ATM in cell apoptosis pathway in bladder cancer [62]. In
addition, lncRNA profile and mRNA profile revealed sig-
nificant changes in PPAR pathway in glioblastoma group
compared with the normal group by target gene-related
pathway analysis, such as ASLNC22381 and ASLNC2081
were found to play roles in glioma signaling pathways [76].
Moreover, the relative abundance of a collection of
lncRNAs in pancreatic ductal adenocarcinoma (PDAC) was
investigated, then intronic lncRNAs differentially expressed
in PDAC metastases were enriched in genes associated to
the MAPK pathway [77].
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Recent studies revealed lncRNAs, like miRNAs, function
as important regulators in gene regulatory networks and
exert crucial roles in cancer progression. LncRNAs have
become new and important players and demonstrated po-
tential applications in clinical diagnosis and treatment. Al-
though a few lncRNAs’ functions have been reported,
there are still many challenges that remain to be solved. In
the future, it would be necessary to further investigate the
functional motifs and secondary or tertiary structure of
lncRNAs, to fully elucidate the diverse gene regulatory
mechanisms of lncRNAs, and to develop new and effect-
ive methods to predict target genes of lncRNAs using
bioinformatics, etc. These endeavors will provide new in-
sights into the complicated gene regulatory network in-
volving lncRNAs, and ultimately provide novel strategies
for cancer diagnosis and therapy.
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